



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>C07D 501/22, A61K 31/545</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 91/00865</b> <b>(43) International Publication Date:</b> 24 January 1991 (24.01.91)
<b>(21) International Application Number:</b> PCT/EP90/01108 <b>(22) International Filing Date:</b> 9 July 1990 (09.07.90) <b>(30) Priority data:</b> 377,668 10 July 1989 (10.07.89) US <b>(71) Applicant:</b> GEMA S.A. [ES/ES]; Via Augusta, 158, E-08006 Barcelona (ES). <b>(72) Inventors:</b> DIAGO MESEGUER, Jose ; Paseo de la Montana, 90, E-08400 Granollers (ES). BEAUS CODES, Rafael ; Via Augusta, 213, E-08021 Barcelona (ES). ALONSO CIRIZA, Santiago ; Traversera de Gracia, 393, E-08025 Barcelona (ES).	<b>(74) Agents:</b> KLEINE DETERS, Johannes et al.; Sandoz AG, Patentabteilung, CH-4002 Basel (CH).  <b>(81) Designated States:</b> AT (European patent), BE (European patent), CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).  <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> A NOVEL STABLE FORM OF CEPHRADINE, PROCESS FOR ITS PRODUCTION AND INTERMEDIATES USED THEREIN  <b>(57) Abstract</b>  The invention relates to a novel stable form of cephradine, processes for its production and intermediates used therein.		

### DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

#### FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TC	Togo
DK	Denmark			US	United States of America

- 1 -

A novel stable form of cephradine, process for its production and Intermediales used therein.

This invention relates to the known, commercially available, antibiotic cephradine. Cephradine is the International Non-Proprietary Name of the compound 7-[D-2-amino-2-(1,4-cyclohexadienyl)acetamido]desacetoxycephalosporanic acid of formula I.



Cephradine was first described in the late 60's and various processes for its production have been described. There is considerable evidence that the product exhibits polymorphism and indeed four polymorphs have been described [Analytical Profiles of Drug Substances, Volume 5, 37-43 (1976)]. For various reasons, the commercially available form is a hydrated form in which the water content is in the range of about 3% to about 6% per weight. This is not a stoichiometric hydrate since the water varies freely in the crystal. The inherent problem with this commercially available form is its poor stability. Thus, it is prone to oxidation to cephalixin (the corresponding product in which the cyclohexadienyl ring is replaced by a benzene ring), to degradation and to coloration. It also has a low bulk density which is a disadvantage since the form is also prone to degradation upon compacting.

- 2 -

United States Patent 3,819,620 describes a dihydrate form of cephradine. This form is reported to have a substantially higher bulk density than the hydrated form referred to above and to be substantially more stable (Analytical Profiles of Drug Substances, *ibid.*). However, it is difficult and expensive to obtain and it is presumably for this and other reasons that this form has not become commercially available.

Belgian Patent 777,789, in the name of Eli Lilly, quite generally describes dimethylformamide complexes of cephalosporins. However, it makes no reference to cephradine and is primarily concerned with  $\alpha$ -aminophenylacetamido-desacetoxycephalosporanic acids such as cephalixin and *p*-hydroxycephalexin (now known as cefadroxil).

It is an object of the present invention to provide a novel stable form of cephradine hydrate, hereinafter referred to as a cephradine SF (stable form). The present invention also provides a novel intermediate in the production of cephradine, namely cephradine dimethylformamide solvate. The present invention finally provides a process for producing cephradine SF.

The cephradine SF of the present invention has essentially the same IR spectrum and a similar or essentially the same X-ray diffraction pattern to the commercially available form of cephradine hydrate referred to above. It also has a water content within the limits specified in the United States Pharmacopoeia for the non-stoichiometric "monohydrate", namely not more than 6% by weight as determined by Karl Fischer analysis and is therefore quite distinct from the previously reported dihydrate. More typically the cephradine SF of the invention has a water content of from about 3 to about 6%, preferably about 3.5% to about 4.5%, by weight.

However, the cephradine SF of the present invention differs in several very important characteristics.

- 3 -

Firstly, the crystals are much larger, and normally are approximately double the size. Apparently, as a result the bulk density is far higher and its tapped density prior to any milling or other particle size reduction procedures is normally at least 0.5 g/ml, and is more usually at least 0.7 g/ml, e.g. 0.7 to 0.8 g/ml and more particularly from 0.75 to 0.8 g/ml, typically from 0.75 to 0.77 g/ml, as compared to the average tapped density of the commercially available hydrate ("monohydrate") form of about 0.45 g/ml. This is important since the cephradine SF of the invention as a result does not require a compacting step for its formulation.

"Tapped Density" as herein refers to density at constant volume and is suitably determined by the following method: approximately 70 to 90 ml of the material (whose tapped density is to be determined) is added to a graduated 100 ml cylinder through a plastic funnel and the bulk volume of the material is read and recorded. The cylinder is placed in a tapping apparatus (e.g. STAV 2003) and is subjected to 1000 taps. The resulting volume is then read and recorded to give the tapped volume. The weight of the material is divided by the tapped volume to give the tapped density.

The cephradine SF of the invention is also much more stable than the commercially available hydrate ("monohydrate") form as determined by conventional stability tests on, for example, coloration. Thus, while commercial forms of cephradine monohydrate show a substantial increase of coloration when subjected to in a closed container to an environment maintained at 40°C and 70% relative humidity for a period of at least 8 weeks (hereinafter referred to as "closed Stress Stability test"), the coloration of the cephradine SF of the invention remains essentially the same. By this is meant that the absorbance (as explained hereinafter) at 450 nm, using sodium carbonate as blank, after the stress test is with the cephradine SF of the invention less than 1, more

- 4 -

particularly less than 0.5, more particularly less than 0.2 after 4 weeks. Even after 8 weeks, the absorbance is still less than 1 typically under 0.5, more particularly under 0.3. In contrast, commercially available cephradine monohydrate shows an absorbance of usually over 1 at four weeks and from 3 to 5 at 8 weeks whether in the closed stress stability test.

In addition, the surprisingly increased stability of the cephradine SF according to the invention is demonstrated by its essentially unchanged cephalixin content when subjected to the same closed stress stability test. In particular, the cephalixin content of the cephradine SF of the invention increases no more than 20%, more typically no more than 15% and usually no more than about 10% by weight after 4 weeks or even 8 weeks of such stress stability conditions. In contrast, commercially available cephradine monohydrate will approximately double in cephalixin content after 8 weeks.

The cephradine SF of the present invention also appears to be less inclined to absorb water upon standing in the atmosphere at room temperature.

The advantages of the cephradine SF of the invention are substantial in terms of ease of formulation and shelf-life. Moreover, the cephradine SF of the invention can be produced in an economic manner in contrast, apparently, to the previously reported, stable dihydrate.

In accordance with the invention, cephradine SF is produced by crystallisation from an aqueous dimethylformamide solution of cephradine.

In one aspect the present invention provides a process for the production of cephradine hydrate comprising preparing an aqueous dimethylformamide solution of cephradine and crystallising the cephradine hydrate therefrom. The cephradine SF may be isolated by

- 5 -

e.g. conventional procedures in beta-lactam chemistry. Crystallisation may be effected e.g. by preparing a super-saturated solution e.g. by pH adjustment and by cooling.

The cephradine used as starting material may be produced by any method for its production and may be in any form. For example, it may be in salt form, such as hydrochloride salt form, or indeed may be in known hydrated forms. In any event, an aqueous solution of the cephradine starting material is preferably first formed, for example by dissolution in aqueous hydrochloric acid at e.g. 5° to 10°C and, if desired or required, the pH may be adjusted to pH 1.5 to 2.5, for example by addition of hydrochloric acid for this purpose. Dimethylformamide is then suitably added to the solution. The quantity of dimethylformamide to be added is conveniently about 1/20 to about 1/5 of the volume of the aqueous layer. The mixture may then be filtered and washed, e.g. with water. The solution is then preferably brought to about 35° to 40° and is then suitably adjusted to a pH of from about 2.4 to 2.8 with a base, such as ammonia, sodium hydroxide or triethylamine at which crystallisation starts. The pH is then preferably adjusted to about 4.7 to 5.1. The resulting suspension is then preferably cooled to a temperature of about 15° to 25°C and filtered. The resulting residue may, if desired be washed with an organic solvent, such as acetone, to obtain cephradine SF of the invention.

In another aspect the present invention provides a process for the production of cephradine hydrate which comprises crystallising said hydrate from an aqueous solution of cephradine dimethylformamide solvate.

Thus the cephradine dimethylformamide solvate resulting from addition of the dimethylformamide to the aqueous cephradine solution may be isolated and optionally purified prior to further processing. The DMF solvate may be produced in accordance with the invention by treating an aqueous solution of cephradine with

- 6 -

dimethylformamide at a temperature of less than about 35°C more usually about 5 to 15°C. The quantity of dimethylformamide to be added may vary within fairly wide limits but in general the volume to be added is one to at least several times the volume of the aqueous layer. The precipitation is preferably accomplished by adjusting the pH of the mixture to about 6.3 to 7.3 by addition of a base, such as ammonia, sodium hydroxide or triethylamine, at for example 30° to 35°C whereupon precipitation begins. The resulting mixture is suitably cooled to about 15° to 25°C and filtered. The resulting DMF solvate may be optionally purified in conventional manner.

The dimethylformamide solvate obtained as described above may then be dissolved in aqueous hydrochloric acid at e.g. 5° to 10°C and, if desired or required, the pH may be adjusted to pH 1.5 to 2.5, for example by addition of hydrochloric acid for this purpose. The mixture may then be filtered and washed, e.g. with water. The solution is then preferably brought to about 35° to 40°C and is then suitably adjusted to a pH of from about 2.4 to 2.8 with a base, such as ammonia, sodium hydroxide or triethylamine at which crystallisation starts. The pH is then preferably adjusted to about 4.7 to 5.1. The resulting suspension is then preferably cooled to a temperature of about 15° to 25°C and filtered. The resulting residue may, if desired be washed with an organic solvent, such as acetone, to obtain cephradine SF of the invention.

The cephradine dimethylformamide solvate described above is new and also forms part of the present invention. It may comprise from at least 0.5, preferably 0.5 to 10, more preferably 0.5 to 3, most preferably about 0.75 to 2.5 moles of dimethylformamide per mole of cephradine. In a preferred embodiment, it contains about 1.00 to about 2 moles of DMF per mole of cephradine, e.g. about 1.5 moles of DMF per mole of cephradine.

In a particularly preferred embodiment it contains from 1.8 to 2.2



moles of DMF per mole of cephradine, especially about 2 moles of DMF per mole of cephradine.

The cephradine SF of the invention may be used in the same manner and, at the doses and in the same indications as for cephradine. The cephradine SF may be worked up into pharmaceutical compositions.

In another aspect the present invention provides a pharmaceutical composition containing cephradine SF in association with a pharmaceutical carrier or diluent, as well as processes for their production.

Such compositions may be for example in the form of capsules, tablets, injectable solutions and suspensions. The compositions may contain from about 0.1 to about 99.9% by weight of cephradine SF.

The following Examples, in which all temperatures are in degrees Centigrade illustrate the invention.

Example 1 Cephadrine stable form (SF)

## a) Cephadrine Dimethylformamide Solvate

-----

To an aqueous solution of about 270 ml, containing approximately 49 g of cephradine in the form of its hydrochloride, (and obtained, after extraction from any suitable reaction mixture of cephradine) 340 ml of dimethylformamide were added, the temperature being maintained at below 35°. The pH was adjusted to 4.3 by addition of ammonia at 30°-35°C and the mixture was stirred for several minutes as precipitation commenced. The pH was further adjusted to 6.6 with ammonia at 30° to 35° and the slurry was then cooled to 20° to 25° and filtered. The cake was washed with 160 ml of DMF and 130 ml of acetone to obtain the heading compound.

MP: approx. 160° to 164°

Analysis: (by weight)

Cephadrine	= 70.6%
Cephalexin	= 1.7%
Water	= 0.5%
DMF	= 25 to 30%

IR: Fig. 1

## b) Cephadrine SF

-----

125 g of cephradine dimethylformamide solvate (as for example produced in step a) above) were suspended in water/conc. HCl (300/12.5) at 5° to 10°C with stirring. The pH was adjusted to 1.6 to 2.0 by addition of hydrochloric acid in order to obtain a complete solution. The solution was filtered and the residue washed with 60 ml of water. The combined filtrate was warmed to 35° to 40°C. The pH was adjusted to 2.4 to 2.8 with triethylamine whereupon precipitation started. The stirring was maintained for

- 9 -

several minutes. The pH was then adjusted to 4.7 to 5.1 with triethylamine and the suspension was cooled to about 25° and filtered. The residue was washed with 270 g of acetone (80% v/v) to obtain the heading compound, m.p. 190° to 200°C (decomp.).

#### Example 2 Cephradine Stable Form (SF)

Example 1 is repeated using in place of ammonia at each instance in step a) the required amount of either sodium hydroxide or triethylamine to bring the pH to that indicated. Cephradine dimethylformamide solvate and the heading compound are likewise obtained.

#### Example 3 Cephradine Stable Form (SF)

50 g of commercially available cephradine hydrate were suspended in a mixture of water and conc. hydrochloric acid (180/7) at 5° to 10°C with stirring. The pH was brought to 1.6 to 2.0 with hydrochloric acid in order to form a complete solution and 16 g of dimethylformamide were added. The solution was filtered and the residue was washed with 35 ml of water. The combined filtrate was warmed to 35° to 40° and the pH brought to 2.8 with aqueous triethylamine. Stirring was continued for several minutes and the pH was finally adjusted to about 4.9 with aqueous triethylamine. The resulting slurry was cooled to room temperature and filtered. The residue was washed with 80% (v/v) acetone and dried to obtain the heading compound, mp 190° to 200°C (decomp.).

#### Example 4 Analytical Data of Cephradine SF vs Commercial Cephradine hydrate

A batch of commercially available cephradine hydrate and a batch of Cephradine SF were subjected to the following stress stability test: about 5 kgs of product, kept in a commercial container in a climatic room at 40°C and 70% relative humidity for 8 weeks. At weekly intervals the batches were analysed inter alia for

- 10 -

cephalexin content, assay and colour increase using conventional procedures described below. The results are summarised in Figures 2, 3 and 4. It will be seen that the cephradine SF of the invention is remarkably stable, judged by any of these parameters, over the 8 week period while the normal commercially available hydrate deteriorates seriously.

Cephalexin Content: Procedure

Equipment: Hewlett-Packard chromatograph 1084 B or similar.

Detector: U.V. at 254 nm.

Column: RP-8 (Hypersil MOS), 10 cm, 5  $\mu$ m or equivalent.

Mobil phase: Phosphate buffer 20 mM., pH 5.0/Methanol (75/25).

Temperature: 40°C.

Flow: 1.5 ml/min.

Injection: 20  $\mu$ l.

Retention time - 120 sec.

$$\% = \frac{VI_M \times W_{st} \times 100}{VI_{st} \times W_M \times (100 - H_M)} \times A_{st}$$

$W_{st}$ : Concentration of standard

$W_M$ : Concentration of sample

$H_M$ : Moisture of sample

$A_{st}$ : Potency of standard (as is)

$VI_M$ : Integration value of the cephalixin peak (sample)

$VI_{st}$ : Integration value of the cephalixin peak (standard)

Solution: a) Phosphate buffer 20 mM., pH 5.0

Weight 2.72 g of  $KH_2PO_4$  and dissolve in 1.000 ml of water

b) Cephalixin standard

Dissolve 100 mg, exactly weighed, in 50 ml of phosphate buffer. Take 1 ml. and complete to 25 ml with the same buffer.

c) Sample

Dissolve 100 mg, exactly weighed, in 50 ml of phosphate buffer.

Assay: HPLC Procedure

Equipment: Hewlett-Packard chromatograph 1084 B or similar.

Detector: U.V. at 254 nm.

Column: RP-8 (Hypersil MOS), 10 cm, 5  $\mu$ m or equivalent.

Mobil phase: Phosphate buffer 20 mM., pH 5.0/Methanol (75/25).

Temperature: 40°C.

Flow: 1.5 ml/min.

- 12 -

Injection: 5 µl.

Retention time - 150 sec.

$$\% = \frac{VI_M \times W_{st} \times 100}{VI_{st} \times W_M \times (100 - H_M)} \times A_{st}$$

$W_{st}$ : Weight of standard

$W_M$ : Weight of sample

$H_M$ : Moisture of the sample

$A_{st}$ : Potency of standard (as is)

$VI_M$ : Integration value of the cephradine peak (sample)

$VI_{st}$ : Integration value of the cephradine peak (standard)

Solutions: a) Phosphate buffer 20 mM., pH 5.0.

Weight 2.72 g of  $KH_2PO_4$  and dissolve in 1.000 ml of water.

b) Cephradine standard

Dissolve 100 mg, exactly weighed, in 50 ml of phosphate buffer.

c) Sample

Dissolve 100 mg, exactly weighed, in 50 ml of phosphate buffer.

Coloration: Procedure

Dissolve 2 g of product in 10 ml of 10% w/v of sodium carbonate.  
Read the absorbance at 450 nm., using sodium carbonate as blank.

Tapped Density

The tapped density of the commercially available cephradine hydrate has an average value of 0.45 g/ml. The tapped density of cephradine SF is 0.75 g/ml.

## WHAT IS CLAIMED IS:

1. Cephadrine hydrate having a water content (Karl-Fischer) of from about 3 to about 6% by weight and a tapped density of at least 0.5 g/ml.
2. Cephadrine hydrate of claim 1 having a tapped density of at least 0.7 g/ml.
3. Cephadrine hydrate of claim 1 having a tapped density of from 0.7 to 0.8 g/ml.
4. Cephadrine hydrate, having a water content (Karl-Fischer) of from about 3 to about 6% by weight, which shows no substantial increase in coloration when kept in a closed container in an environment maintained at 40°C and 70% relative humidity over a period of 8 weeks.
5. Cephadrine hydrate of claim 3, which shows absorbance at 450 nm of less than 1 after said 8 weeks.
6. Cephadrine hydrate of claim 1, having a water content (Karl-Fischer) of from about 3 to about 6% by weight, which shows an increase in cephalixin content of no greater than 20% by weight when kept in a closed container in an environment maintained at 40°C and 70% relative humidity over a period of 8 weeks.
7. A process for the production of cephradrine hydrate comprising preparing an aqueous dimethylformamide solution of cephradrine and crystallising the cephradrine hydrate therefrom.
8. A process for the production of cephradrine hydrate which comprises crystallising said hydrate from an aqueous solution of



- 15 -

cephradine dimethylformamide solvate.


9. Cephadrine dimethylformamide solvate.

10. A pharmaceutical composition comprising cephradine hydrate according to any one of claims 1 to 6 or produced by a process according to claim 7 or 8 in association with a pharmaceutical carrier or diluent.


11. A process for producing a pharmaceutical composition which comprises working up a cephradine hydrate according to any one of claims 1 to 6 or produced by a process according to claim 7 or 8 with a pharmaceutical carrier or diluent.

1/4

FIG. 1




SUBSTITUTE SHEET

**SUBSTITUTE SHEET**

3/4


Figure 3

## ASSAY



SUBSTITUTE SHEET


4/4



SUBSTITUTE SHEET

# INTERNATIONAL SEARCH REPORT

International Application No PCT/EP 90/01108

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>5</sup> According to International Patent Classification (IPC) or to both National Classification and IPC <b>IPC5: C 07 D 501/22, A 61 K 31/545</b>		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
IPC5	A 61 K; C 07 D	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	Klaus Florey et al "Analytical Profiles of Drug Substances", 1976, Academic Press,, see page 37- page 45 see particularly page 37  --	1-6
Y	US, A, 3819620 (FRIEDRICH DÜRSCH ET AL) 25 June 1974, see the whole document  --	1-11
Y	BE, A, 777789 (ELI LILLY AND COMPANY) 6 July 1972, see particularly page 1, example 1 and 5 and the claims  --	7-11
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
10th October 1990		30. 10. 90
International Searching Authority		Signature of Authorized Officer
EUROPEAN PATENT OFFICE		R.J. Eernisse 

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	DE, C2, 2718741 (BRISTOL-MYERS CO) 21 March 1985, see particularly pages 6-8 ---	7-11
A	EP, A2, 0287751 (RIFAR S.R.L.) 26 October 1988, see page 7 --	7-11
A	EP, A2, 0302145 (RIFAR S.R.L.) 8 February 1989, see example 3 and 7 -- -----	7-11

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO. PCT/EP 90/01108**

SA 38641

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 28/08/90. The European Patent office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A- 3819620	25/06/74	AT-B- 322740	10/06/75
		AU-B- 475833	02/09/76
		AU-D- 5507473	07/11/74
		BE-A- 800373	03/12/73
		CA-A- 1004220	25/01/77
		CH-A- 582185	30/11/76
		DE-A-C- 2326880	20/12/73
		FR-A-B- 2186234	11/01/74
		GB-A- 1426266	25/02/76
		JP-C- 1050918	26/06/81
		JP-A- 49041520	18/04/74
		JP-B- 55044754	13/11/80
		NL-A- 7307321	04/12/73
		SE-B-C- 409714	03/09/79
		US-A- 3928591	23/12/75
BE-A- 777789	06/07/72	AT-A-B- 314731	15/03/74
		CA-A- 1010848	24/05/77
		CH-A- 547311	29/03/74
		DE-A- 2202227	30/11/72
		FR-A- 2122987	01/09/72
		GB-A- 1336802	14/11/73
		LU-A- 64635	23/08/72
		NL-A- 7200712	24/07/72
		SE-B-C- 380269	03/11/75
		US-A- 3781282	25/12/73
DE-C2- 2718741	21/03/85	AT-B- 350183	10/05/79
		AU-B- 510338	19/06/80
		AU-D- 2460777	02/11/78
		BE-A- 853974	26/10/77
		CA-A- 1115268	29/12/81
		CH-A- 632270	30/09/82
		FR-A-B- 2349589	25/11/77
		FR-A-B- 2365570	21/04/78
		GB-A- 1532682	22/11/78
		JP-C- 1370381	25/03/87
		JP-A- 52142091	26/11/77
		JP-A- 60185718	21/09/85
		LU-A- 77202	22/11/77
		NL-A- 7704618	31/10/77
		SE-B-C- 437521	04/03/85
		SE-A- 7704739	01/12/77
		US-E- RE31730	13/11/84

For more details about this annex: see Official Journal of the European Patent Office, No. 12/82



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**